Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12759)
All Articles published online
|
Publishing Process of This Article
|
Jul 15, 2017 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kayhanian H, Smyth EC, Braconi C. Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol 2017; 9(7): 268-280 [PMID: 28808500 DOI: 10.4251/wjgo.v9.i7.268] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v9/i7/268.htm |
| Number | Citing Articles |
| 1 |
Marin Strijker, Ali Belkouz, Lydia G. van der Geest, Thomas M. van Gulik, Jeanin E. van Hooft, Vincent E. de Meijer, Nadia Haj Mohammad, Philip R. de Reuver, Joanne Verheij, Judith de Vos-Geelen, Johanna W. Wilmink, Bas Groot Koerkamp, Heinz-Josef Klümpen, Marc G. Besselink. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncologica 2019; 58(7): 1048 doi: 10.1080/0284186X.2019.1590634
|
| 2 |
Samantha Sarcognato, Iris E. M. de Jong, Luca Fabris, Massimiliano Cadamuro, Maria Guido. Necroptosis in Cholangiocarcinoma. Cells 2020; 9(4): 982 doi: 10.3390/cells9040982
|
| 3 |
Tommaso M Manzia, Alessandro Parente, Ilaria Lenci, Bruno Sensi, Martina Milana, Carlo Gazia, Alessandro Signorello, Roberta Angelico, Giuseppe Grassi, Giuseppe Tisone, Leonardo Baiocchi. Moving forward in the treatment of cholangiocarcinoma. World Journal of Gastrointestinal Oncology 2021; 13(12): 1939-1955 doi: 10.4251/wjgo.v13.i12.1939
|
| 4 |
Wei-xun Chen, Gan-xun Li, Zheng-nan Hu, Peng Zhu, Bi-xiang Zhang, Ze-yang Ding. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis. Medicine 2019; 98(45): e17832 doi: 10.1097/MD.0000000000017832
|
| 5 |
Thorsten Oliver Götze, Melanie Prause, Salah-Eddin Al-Batran. Adjuvante Studie PEARLDIFER. Forum 2023; 38(1): 70 doi: 10.1007/s12312-022-01160-x
|
| 6 |
Wei Zhong, Lianzhi Dai, Jing Liu, Song Zhou. Cholangiocarcinoma‑associated genes identified by integrative analysis of gene expression data. Molecular Medicine Reports 2018; doi: 10.3892/mmr.2018.8594
|
| 7 |
Manuel Scimeca, Valentina Rovella, Valeria Palumbo, Maria Paola Scioli, Rita Bonfiglio, Gerry Melino, Mauro Piacentini, Luigi Frati, Massimiliano Agostini, Eleonora Candi, Alessandro Mauriello. Programmed Cell Death Pathways in Cholangiocarcinoma: Opportunities for Targeted Therapy. Cancers 2023; 15(14): 3638 doi: 10.3390/cancers15143638
|
| 8 |
Oded Jacobi, Jeffrey S. Ross, Tal Goshen-Lago, Riad Haddad, Assaf Moore, Aaron Sulkes, Baruch Brenner, Irit Ben-Aharon. ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway. Oncology Research and Treatment 2021; 44(1-2): 20 doi: 10.1159/000511919
|
| 9 |
Meena Sadaps, Davendra P.S. Sohal. Remarkable Case of Dual BRAF and MEK Inhibition in Cholangiocarcinoma. JCO Precision Oncology 2019; (3): 1 doi: 10.1200/PO.19.00056
|
| 10 |
Chen Liu, Min Wang, Haitao Lv, Bing Liu, Xueqiang Ya, Weihong Zhao, Wenbin Wang. CEACAM6 promotes cholangiocarcinoma migration and invasion by inducing epithelial‑mesenchymal transition through inhibition of the SRC/PI3K/AKT signaling pathway. Oncology Letters 2021; 23(1) doi: 10.3892/ol.2021.13157
|
| 11 |
Samantha Sarcognato, Enrico Gringeri, Matteo Fassan, Michela Di Giunta, Valeria Maffeis, Vincenza Guzzardo, Umberto Cillo, Maria Guido. Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma. Virchows Archiv 2019; 474(1): 29 doi: 10.1007/s00428-018-2478-y
|
| 12 |
Thorsten O. Goetze, Wolf O. Bechstein, Ulli Simone Bankstahl, Tobias Keck, Alfred Königsrainer, Sven A. Lang, Claudia Pauligk, Pompiliu Piso, Arndt Vogel, Salah-Eddin Al-Batran. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)– the AIO/ CALGP/ ACO- GAIN-trial –. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-6610-4
|
| 13 |
Mitesh J. Borad, Li‐Yuan Bai, Donald Richards, Kabir Mody, Joleen Hubbard, Sun Young Rha, John Soong, Daniel McCormick, Emmett Tse, Daniel O'Brien, Ahmad Bayat, Daniel Ahn, S. Lindsey Davis, Joon Oh. Park, Do‐Youn Oh. Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study. Hepatology 2023; 77(3): 760 doi: 10.1002/hep.32804
|
| 14 |
Sai Sandeep Annamaraju, Sai Charitha Mullaguri, Ravikanth Vishnubhotla, Rama Krishna Kancha. Biomedical Aspects of Solid Cancers. 2024; : 85 doi: 10.1007/978-981-97-1802-3_8
|
| 15 |
Nicolás Goldaracena, Andre Gorgen, Gonzalo Sapisochin. Current status of liver transplantation for cholangiocarcinoma. Liver Transplantation 2018; 24(2): 294 doi: 10.1002/lt.24955
|
| 16 |
Keun Soo Ahn, Koo Jeong Kang. Molecular heterogeneity in intrahepatic cholangiocarcinoma. World Journal of Hepatology 2020; 12(12): 1148-1157 doi: 10.4254/wjh.v12.i12.1148
|
| 17 |
Alessandra Gentilini, Alessandra Caligiuri, Chiara Raggi, Krista Rombouts, Massimo Pinzani, Giulia Lori, Margherita Correnti, Pietro Invernizzi, Elisabetta Rovida, Nadia Navari, Sabina Di Matteo, Domenico Alvaro, Jesus M. Banales, Pedro Rodrigues, Carlotta Raschioni, Matteo Donadon, Luca Di Tommaso, Fabio Marra. CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019; 1865(9): 2246 doi: 10.1016/j.bbadis.2019.04.020
|
| 18 |
Kira Astakhova, Roslyn Ray, Maria Taskova, Jesper Uhd, Annika Carstens, Kevin Morris. “Clicking” Gene Therapeutics: A Successful Union of Chemistry and Biomedicine for New Solutions. Molecular Pharmaceutics 2018; 15(8): 2892 doi: 10.1021/acs.molpharmaceut.7b00765
|
| 19 |
Marianeve Carotenuto, Alessandra Sacco, Laura Forgione, Nicola Normanno. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy 2022; : 200 doi: 10.37349/etat.2022.00079
|
| 20 |
Aparna Kalyan, Rachna T Shroff. Cholangiocarcinoma: The Present and Future of Targeted Therapies. Oncology & Haematology 2022; 18(1): 9 doi: 10.17925/OHR.2022.18.1.9
|
| 21 |
Pasquale Lombardi, Donatella Marino, Elisabetta Fenocchio, Giovanna Chilà, Massimo Aglietta, Francesco Leone. Emerging molecular target antagonists for the treatment of biliary tract cancer. Expert Opinion on Emerging Drugs 2018; 23(1): 63 doi: 10.1080/14728214.2018.1444749
|
| 22 |
Lei Zhang, Martin H. Bluth, Amarpreet Bhalla. Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract. Clinics in Laboratory Medicine 2018; 38(2): 367 doi: 10.1016/j.cll.2018.03.003
|
| 23 |
Hongsik Kim, Ryul Kim, Hye Ryeon Kim, Hyunji Jo, Hana Kim, Sang Yun Ha, Joon Oh Park, Young Suk Park, Seung Tae Kim. HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.834104
|